Plasma microRNAs as biomarkers for myotonic dystrophy type 1

Neuromuscular Disorders

Volumn 24, Issue 6, 2014, Pages 509-515

  Perfetti, Alessandra ^a   Greco, Simona ^a   Bugiardini, Enrico ^a,b   Cardani, Rosanna ^a   Gaia, Paola ^a   Gaetano, Carlo ^c   Meola, Giovanni ^a,b   Martelli, Fabio ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Biomarker; MicroRNA; Myotonic dystrophy; Patients; Plasma

Indexed keywords

MICRORNA; MICRORNA 133A; MICRORNA 140 3P; MICRORNA 191; MICRORNA 193B; MICRORNA 27B; MICRORNA 454; MICRORNA 574; MICRORNA 885 5P; MICRORNA 886 3P; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MUSCLE STRENGTH; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; BLOOD; GENETICS; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOTONIC DYSTROPHY; ROC CURVE;

EID: 84901069935     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2014.02.005     Document Type: Article

References (34)

1. Udd B., Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012, 11:891-905.
2. Brook J.D., McCurrach M.E., Harley H.G., et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992, 69:385.
3. Gagnon C., Meola G., Hebert L.J., et al. Report of the first outcome measures in myotonic dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011. Neuromuscul Disord 2013.
4. Kornblum C., Lutterbey G., Bogdanow M., et al. Distinct neuromuscular phenotypes in myotonic dystrophy types 1 and 2: a whole body highfield MRI study. J Neurol 2006, 253:753-761.
5. Hiba B., Richard N., Hebert L.J., et al. Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI. J Magn Reson Imaging 2012, 35:678-685.
6. Kumar A., Agarwal S., Agarwal D., Phadke S.R. Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder. Gene 2013, 522:226-230.
7. Bartel D.P. microRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
8. Eisenberg I., Alexander M.S., Kunkel L.M. miRNAS in normal and diseased skeletal muscle. J Cell Mol Med 2009, 13:2-11.
9. Greco S., Perfetti A., Fasanaro P., et al. Deregulated microRNAs in myotonic dystrophy type 2. PLoS ONE 2012, 7:e39732.
10. Greco S., De Simone M., Colussi C., et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J 2009, 23:3335-3346.
11. Perbellini R., Greco S., Sarra-Ferraris G., et al. Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 2011, 21:81-88.
12. Chen X., Ba Y., Ma L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
13. Cacchiarelli D., Legnini I., Martone J., et al. miRNAs as serum biomarkers for Duchenne muscular dystrophy. EMBO Mol Med 2011, 3:258-265.
14. Vignier N., Amor F., Fogel P., et al. Distinctive serum miRNA profile in mouse models of striated muscular pathologies. PLoS ONE 2013, 8:e55281.
15. Mizuno H., Nakamura A., Aoki Y., et al. Identification of muscle-specific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS ONE 2011, 6:e18388.
16. Moxley R.T., Meola G., Udd B., Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002, 12:306-317.
17. Meola G. Clinical and genetic heterogeneity in myotonic dystrophies. Muscle Nerve 2000, 23:1789-1799.
18. Kamsteeg E.J., Kress W., Catalli C., et al. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet 2012, 20:1203-1208.
19. Valaperta R., Sansone V., Lombardi F., et al. Identification and characterization of DM1 patients by a new diagnostic certified assay: neuromuscular and cardiac assessments. Biomed Res Int 2013, 2013:958510.
20. Mathieu J., Boivin H., Meunier D., Gaudreault M., Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001, 56:336-340.
21. Compston A. Aids to the investigation of peripheral nerve injuries. Medical Research Council: Nerve Injuries Research Committee. His majesty's stationery office: 1942; pp. 48 (iii) and 74 figures and 7 diagrams; with aids to the examination of the peripheral nervous system. By Michael O'Brien for the guarantors of brain. Saunders Elsevier: 2010; pp. [8] 64 and 94 figures. Brain 2010, 133:2838-2844.
22. D'Alessandra Y., Devanna P., Limana F., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010, 31:2765-2773.
23. Erdreich L.S., Lee E.T. Use of relative operating characteristic analysis in epidemiology. A method for dealing with subjective judgement. Am J Epidemiol 1981, 114:649-662.
24. Henderson A.R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993, 30(Pt 6):521-539.
25. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
26. Greiner M., Pfeiffer D., Smith R.D. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000, 45:23-41.
27. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
28. Anindo M.I., Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg 2012, 10:443-449.
29. Di Stefano V., Zaccagnini G., Capogrossi M.C., Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol 2011, 55:111-118.
30. Scholer N., Langer C., Dohner H., Buske C., Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010, 38:1126-1130.
31. Muroya S., Taniguchi M., Shibata M., et al. Profiling of differentially expressed microRNA and the bioinformatic target gene analyses in bovine fast- and slow-type muscles by massively parallel sequencing. J Anim Sci 2012, 91:90-103.
32. Gibson G., Asahara H. microRNAs and cartilage. J Orthop Res 2013, 31:1333-1344.
33. Cordani N., Pisa V., Pozzi L., Sciorati C., Clementi E. Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation. Stem Cells 2013, 10.1002/stem.1587.
34. Stadler P.F., Chen J.J., Hackermuller J., et al. Evolution of vault RNAs. Mol Biol Evol 2009, 26:1975-1991.